Use of An Implantable Wireless Pulmonary Pressure Monitor during Transition of Therapy in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a chronic and rapidly progressive disease, characterized by remodeling and vasoconstriction of the pulmonary vasculature, leading to increased pulmonary vascular resistance. PAH continues to be life-threatening, with high mortality despite advances in therapy. Current guidelines support the use of combination therapies that target the endothelin, nitric-oxide, and prostacyclin pathways. However, prostacyclin therapy has long been considered the gold standard for high risk patients, and intravenous (IV) prostacyclin therapy is the only medication shown to improve survival in PAH.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Sophia Airhart, Nathan Verlinden, Nima Badie, Amresh Raina, Raymond Benza Tags: Research Correspondence Source Type: research
More News: Cardiology | Heart | Heart Transplant | Hypertension | Lung Transplant | Transplant Surgery | Transplants